Szyman Catherine M.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed Apr 11, 2022
- Accession no.
- 0001225208-22-005751
- Filed
- Apr 11, 2022
- Trade date
- Apr 11, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.44M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Szyman Catherine M.CIK 0001438538 | Officer (CVP, Critical Care) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2022 | Common Stock | MOption exerciseAcquired | +20,000 | $21.76 | +$435,200 | 47,568.66 | Direct | |
| Apr 11, 2022 | Common Stock | SSaleDisposed | −3,600 | $122.12F2 | −$439,632 | 43,968.66 | Direct | |
| Apr 11, 2022 | Common Stock | SSaleDisposed | −6,579 | $123.00F3 | −$809,217 | 37,389.66 | Direct | |
| Apr 11, 2022 | Common Stock | SSaleDisposed | −9,821 | $121.37F4 | −$1,191,974.77 | 27,568.66 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2022 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 23,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $121.8500 to $122.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $122.9600 to $123.4000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $120.8475 to $121.8300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.